sitagliptin Sitagliptin Trade Name: Januvia Drug Class: oral hypoglycemics Mechanism of Action: An inhibitor of dipeptidyl peptidase-4 (DPP-4), a protease that degrades the incretin GLP-1 Incretins are hormones released from the GI tract in response to nutrient ingestion Incretins potentiate glucose-stimulated insulin secretion from beta cells in the pancreas As a result of inhibiting DPP-4, increased or prolonged GLP-1 levels are able to potentiate the secretion of insulin by the pancreas The effect produced by DPP-4 inhibitors is dependent on endogenous GLP-1 levels, and produce a modest effect on GLP-1 activity compared to giving GLP-1 receptor agonists (hence DPP-4 inhibitors do not have the same impact to produce weight loss as GLP-1 agonists)
Enhanced treatment tolerance: Research indicates IV vitamin C may help people tolerate chemotherapy better, potentially reducing fatigue, nausea, and other side effects while maintaining treatment effectiveness
Further work demonstrated that BETP positively modulates GLP-1R function through covalent modification of cysteine 347 located on the third intracellular loop ( 23 )
Article PubMed Google Scholar Drucker, D
Companies that combine strong clinical performance with convenience, manufacturability and access will be in a much better position to succeed in the real world
your body creates a hormone called ghrelin that sends signals to your brain to eat